Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Publisher Correction: Molecular factors predicting minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

  • By

  • Florence Magrangeas

  • Mia Cherkaoui

  • Victor Bessonneau-Gaborit

  • Jennifer Derrien

  • Céline Chevalier

  • Catherine Guérin-Charbonnel

  • Benjamin Diamond

  • Mehmet Kemal Samur

  • Cyrille Hulin

  • Denis Caillot

  • Lionel Karlin

  • Bertrand Arnulf

  • Ola Landgren

  • Nikhil C. Munshi

  • Hervé Avet-Loiseau

  • Ludovic Martinet

  • Jill Corre

  • Aurore Perrot

  • Philippe Moreau

  • Cyrille Touzeau

  • Stéphane Minvielle

  • Eric Letouzé

  • November 3, 2026

Share

Clinical Scorecard: Publisher Correction: Molecular factors predicting minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

At a Glance

CategoryDetail
ConditionNot specified in the correction context.
Key MechanismsNot specified in the correction context.
Target PopulationNot specified in the correction context.
Care SettingPublisher correction to an article abstract.

Key Highlights

  • The correction was published online on 19 October 2026.
  • The original abstract had incomplete wording in sentences seven and eight.
  • The amended text appears in both the HTML and PDF versions.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Not specified in the correction context.

          The correction context provides no treatment or prescribing details.

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

            • by Florence Magrangeas, Mia Cherkaoui, Victor Bessonneau-Gaborit, Jennifer Derrien, Céline Chevalier, Catherine Guérin-Charbonnel, Benjamin Diamond, Mehmet Kemal Samur, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Ola Landgren, Nikhil C. Munshi, Hervé Avet-Loiseau, Ludovic Martinet, Jill Corre, Aurore Perrot, Philippe Moreau, Cyrille Touzeau, Stéphane Minvielle, Eric Letouzé

            • November 3, 2026

            Related Content

            Correction: Evaluation of the Applicability of Synthetic Data in the Development of Colorectal Cancer Survival Prediction Models: External Validation of Advanced Machine Learning Models Based on National Cancer Data Center Data

            Mailed Fecal Immunochemical Tests—From Efficacy to Implementation

            CAR NK Cells Target Cancer and Autoimmunity

            mRNA nanoparticles reprogram NK cells in vivo, inducing tumor remissions and reducing autoimmune liver damage in mice.

            • October 21, 2026

            • 2 min